Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
DNA damage response inhibitors are widely used anti-cancer agents that have potent activity against tumor cells with deficiencies in various DNA damage response proteins such as BRCA1/2. Inhibition of other proteins in this pathway including PARP, DNA-PK, WEE1, CHK1/2, ATR, or ATM can sensitize canc...
-д хадгалсан:
| Үндсэн зохиолчид: | , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Frontiers Media S.A.
2022-10-01
|
| Цуврал: | Frontiers in Oncology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.frontiersin.org/articles/10.3389/fonc.2022.998388/full |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|